Moxonidine

CARDIOVASCULAR SYSTEM

Key facts

Moxonidine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1991. DrugCentral lists 8 molecular targets, including NISCH, ADRA2B and Nisch. Recorded indications include Essential hypertension.

• Molecular targets: NISCH, ADRA2B, Nisch and ADRA2A (8 listed in DrugCentral).
• Indications: Essential hypertension.
• ATC code: C02AC05 (Imidazoline receptor agonists).
• Molecular formula: C9H12ClN5O; molecular weight 241.68 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Essential hypertension

Mechanism & targets

Molecular targets (8)

Target	Gene	Action	Activity
Nischarin	NISCH	agonist	Ki 8.38
Alpha-2B adrenergic receptor	ADRA2B	agonist	IC50 7.50
Nischarin	Nisch	unknown	Ki 7.11
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.82
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 6.40
5-hydroxytryptamine receptor 1A	Htr1a	unknown	IC50 6.15
Alpha-2B adrenergic receptor	Adra2b	unknown	Ki 6.00
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 5.70

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1991-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
C02AC05	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIADRENERGIC AGENTS, CENTRALLY ACTING › Imidazoline receptor agonists
C02LC05	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION › Imidazoline receptor agonists in combination with diuretics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Renal impairment	235.1
Acute kidney injury	178.1
Serositis	166.2
Hyperkalaemia	163.2
Body mass index abnormal	152.9
Central nervous system lupus	138.7
Product prescribing error	137.2
Cardiac failure	123.4
Hypertensive crisis	118.9
Lupus nephritis	98.8
General physical health deterioration	91.7
Labelled drug-drug interaction medication error	87.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Moxonidine is on its molecule page.

• Molecular formula: C₉H₁₂ClN₅O
• Molecular weight: 241.68 g/mol
• CAS number: 75438-57-2
• InChIKey: WPNJAUFVNXKLIM-UHFFFAOYSA-N
• PubChem CID: 4810

COC1=NC(C)=NC(Cl)=C1NC1=NCCN1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Moxonidine used for?

DrugCentral lists the following indications for Moxonidine: Essential hypertension.

How does Moxonidine work?

Its molecular targets in DrugCentral include NISCH (agonist), ADRA2B (agonist), Nisch and ADRA2A.

When was Moxonidine first approved?

Moxonidine was first approved by the YEAR INTRODUCED in 1991.

What is the chemical formula of Moxonidine?

Moxonidine has the molecular formula C9H12ClN5O and a molecular weight of 241.68 g/mol.

Sources

• DrugCentral drug card 1856 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL19236 — compound record and bioactivity
• PubChem CID 4810 — chemical identifiers
• DrugBank DB09242 — drug record
• FDA UNII CC6X0L40GW — substance identity
• UniProt Q9Y2I1 (NISCH) — target protein
• UniProt P18089 (ADRA2B) — target protein
• UniProt P08913 (ADRA2A) — target protein
• UniProt P08908 (HTR1A) — target protein
• UniProt P18825 (ADRA2C) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.